Kovitz Investment Group Partners LLC Takes Position in Haleon plc (NYSE:HLN)

Kovitz Investment Group Partners LLC acquired a new position in shares of Haleon plc (NYSE:HLN) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 12,919 shares of the company’s stock, valued at approximately $137,000.

Several other large investors have also made changes to their positions in the company. HighTower Advisors LLC grew its position in Haleon by 27.2% during the third quarter. HighTower Advisors LLC now owns 350,795 shares of the company’s stock valued at $3,701,000 after acquiring an additional 74,970 shares during the period. Chartwell Investment Partners LLC grew its holdings in shares of Haleon by 107.8% during the 3rd quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock worth $5,030,000 after purchasing an additional 246,594 shares during the period. Townsquare Capital LLC increased its position in Haleon by 29.8% during the 3rd quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock worth $5,032,000 after purchasing an additional 109,217 shares in the last quarter. FORA Capital LLC purchased a new position in Haleon in the third quarter valued at approximately $1,026,000. Finally, Crossmark Global Holdings Inc. raised its holdings in Haleon by 55.6% in the third quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company’s stock valued at $5,087,000 after buying an additional 171,877 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Haleon stock opened at $9.76 on Friday. The firm has a market capitalization of $44.18 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The stock’s 50 day moving average price is $9.75 and its 200 day moving average price is $9.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.